» Articles » PMID: 33833547

Interferon-λ3 Exacerbates the Inflammatory Response to Microbial Ligands: Implications for SARS-CoV-2 Pathogenesis

Overview
Journal J Inflamm Res
Publisher Dove Medical Press
Date 2021 Apr 9
PMID 33833547
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Interferon lambdas (IFN-λs) are antiviral cytokines that restrict pathogen infection and dissemination at barrier surfaces. Controlled expression of IFN-λs efficiently eliminates acute infections by activating a suite of interferon stimulated genes that inhibit viral propagation and activate local immune cells. Excessive or prolonged production of IFN-λs can however mediate tissue inflammation and disrupt epithelial barriers in both viral and non-viral disease. The mechanism by which IFN-λs drive this disease pathogenesis is poorly understood but may be caused by IFN-λ-mediated amplification of other innate immune signaling pathways.

Methods: Monocyte-derived macrophages were differentiated ± IFN-λ3 and treated with KDO-lipid A, poly I:C or zymosan, representing bacterial, viral or fungal ligands, respectively. Transcriptome and protein expression were quantified by RNA sequencing/PCR and ELISA/bead array, respectively. Bioinformatic analysis was used to define transcription factor profiles and signaling pathways amplified by IFN-λ3. Finally, the SARS-CoV-2 dataset GSE152075 was queried to compare the effects of versus expression in relation to viral load and nasopharyngeal transcriptomes.

Results: IFN-λ3 exacerbated inflammatory and chemotactic responses unique to each microbial ligand, as measured by RNA sequencing and by ELISA/bead array. Functional annotation identified pathways amplified by IFN-λ3, including inflammasome activation. Inflammasome amplification was confirmed in vitro, as measured by caspase 1 activity and IL-1β cleavage. Lastly, SARS-CoV-2 infected nasopharyngeal transcriptomes expressing IFN-λs but not IFN-αs were implicated in myeloid cell-driven pathogenesis including neutrophil degranulation, complement and coagulation cascades.

Discussion: These data suggest that IFN-λs contribute to disease pathology by exacerbating innate immune responses during chronic or severe disease states. IFN-λs may contribute to SARS-CoV-2 disease severity, however further study is required to confirm true causation.

Citing Articles

IFN Lambda Deficiency Contributes to Severe COVID-19 Outcomes.

Zaleska A, Dor-Wojnarowska A, Radlinska A, Rorat M, Szymanski W, Gajewski A Int J Mol Sci. 2024; 25(19).

PMID: 39408857 PMC: 11476353. DOI: 10.3390/ijms251910530.


Interferon-λ3 rs12979860 can regulate inflammatory cytokines production in pulmonary fibrosis.

Hamdi E, Bekhit A, Higazi A, Ahmed A, Hussein Kasem A, Najim M Saudi Pharm J. 2023; 31(11):101816.

PMID: 37876736 PMC: 10590737. DOI: 10.1016/j.jsps.2023.101816.


Influence of polymorphic variations of IFNL, HLA, and IL-6 genes in severe cases of COVID-19.

Araujo A, Sgorlon G, Aguiar L, Cidrao M, Teixeira K, Salcedo J Exp Biol Med (Maywood). 2023; 248(9):787-797.

PMID: 37452704 PMC: 10350587. DOI: 10.1177/15353702231181343.


Validation of the severe COVID-19 prognostic value of serum IL-6, IFN-λ3, CCL17, and calprotectin considering the timing of clinical need for prediction.

Yamamoto K, Ohsiro Y, Suzuki T, Suzuki M, Miura S, Nagashima M PLoS One. 2023; 18(3):e0279897.

PMID: 36996138 PMC: 10062661. DOI: 10.1371/journal.pone.0279897.


Relationship between Anti-SARS-CoV-2 S Abs and IFN-λ3 Levels in the Administration of Oxygen following COVID-19 Vaccination.

Takeshita Y, To Y, Kurosawa Y, Kinouchi T, Tsuya K, Tada Y Immunohorizons. 2023; 7(1):97-105.

PMID: 36645852 PMC: 10563441. DOI: 10.4049/immunohorizons.2200093.


References
1.
Newman A, Steen C, Liu C, Gentles A, Chaudhuri A, Scherer F . Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019; 37(7):773-782. PMC: 6610714. DOI: 10.1038/s41587-019-0114-2. View

2.
Sa Ribero M, Jouvenet N, Dreux M, Nisole S . Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathog. 2020; 16(7):e1008737. PMC: 7390284. DOI: 10.1371/journal.ppat.1008737. View

3.
Baldridge M, Lee S, Brown J, McAllister N, Urbanek K, Dermody T . Expression of on Intestinal Epithelial Cells Is Critical to the Antiviral Effects of Interferon Lambda against Norovirus and Reovirus. J Virol. 2017; 91(7). PMC: 5355594. DOI: 10.1128/JVI.02079-16. View

4.
Suzaki Y, Hamada K, Nomi T, Ito T, Sho M, Kai Y . A small-molecule compound targeting CCR5 and CXCR3 prevents airway hyperresponsiveness and inflammation. Eur Respir J. 2007; 31(4):783-9. DOI: 10.1183/09031936.00111507. View

5.
Getts D, Chastain E, Terry R, Miller S . Virus infection, antiviral immunity, and autoimmunity. Immunol Rev. 2013; 255(1):197-209. PMC: 3971377. DOI: 10.1111/imr.12091. View